Navigation Links
Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
Date:3/30/2009

t problems, such as chest pain or fainting.

VYVANSE should not be taken if you or your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.

Tell the doctor before taking VYVANSE if you or your child is being treated for or has symptoms of depression (sadness, worthlessness, or hopelessness) or bipolar disorder; has abnormal thought or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell the doctor immediately if you or your child develops any of these conditions or symptoms while taking VYVANSE.

Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.

Talk to your health care provider if your child experiences slowing of growth (height and weight). Children should have their height and weight checked periodically while taking VYVANSE. Your healthcare provider may stop VYVANSE treatment if a problem is found during these check-ups.

VYVANSE was generally well tolerated in clinical studies. The most common side effects reported in studies of VYVANSE were: children - decreased appetite, difficulty falling asleep, stomachache, and irritability; adult - decreased appetite, difficulty falling asleep, and dry mouth.

Aggression, new abnormal thoughts/behaviors, mania, growth suppression, worsening of motion or verbal tics,
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Publication of Shire plcs Annual Report 2008
2. Shires Project Playground Gives Boost to Philadelphia
3. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
4. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
5. Shire Announces Opening of Office in Japan
6. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
7. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
8. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
9. Shire plc: Change to Directors Details
10. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
11. Shires New Product Portfolio Delivers Strong Quarterly Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
(Date:7/10/2014)... 10, 2014 EvoDerma ’s NOOME Anti-Aging ... rejuvenating device now comes with a second treatment cup to ... , The new cup is thinner on the edges for ... target rough, thin and uneven surfaces on the face, neck ... a stimulating treatment on areas such as the cheeks and ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... a Financial Crisis, Draws Regional Biopharmaceutical Executives, Investment Leaders ... Biotech companies throughout the country are reeling from the ... funds slated to run out of cash before 2010, ... a life sciences symposium presented by Yankee ...
... Spectral Diagnostics Inc. (TSX:SDI), a company developing products ... findings demonstrating the Toraymyxin(TM) cartridge, a blood purification ... added to conventional therapy, significantly improved hemodynamics and ... with severe sepsis and septic shock. The article ...
... can anticipate a future event and prepare for it, ... Science. In a paper that appeared today in ... and research associate Dr. Orna Dahan of the Institute,s ... Gal Romano of Tel Aviv University, examined microorganisms living ...
Cached Biology Technology:Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 2Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 3Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 4Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 5Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial 2Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial 3Israeli scientists show bacteria can plan ahead 2Israeli scientists show bacteria can plan ahead 3
(Date:7/11/2014)... to study the proteins that let nerve cells send ... stumbled upon a biological tactic that may offer a ... a safe and environmentally responsible way. , Their ... one species and harmless for a closely related onesuggests ... without harming beneficial species like bees. A summary of ...
(Date:7/10/2014)... Fe, Albuquerque, and other major cities in New Mexico, ... treated municipal wastewater rather than precious potable water supplies. ... 40% of all golf courses receive treated effluent. Reusing ... , Additionally, golf courses and homeowners alike fertilize their ... fertilizer is nitrate. A New Mexico State University turfgrass ...
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP ... Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and ... in United States District Court, Middle District of ... on behalf of a class consisting of all ... Provectus securities between December 17, 2013 and May ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... fathers who are active in their children,s upbringing can significantly ... Now, a new study by University of South Florida ... born may play an important role in preventing death during ... is black. The USF team sought to evaluate ...
... RICHMOND, Va. , June 17 Commercializing University Technology ... 29 presented by LeClairRyan and a panel of industry experts from ... , , ... rise again, entrepreneurs, start-ups and emerging businesses should investigate all options to ...
... gestures have intentional meaning and are made with the ... and Richard Byrne from the University of St. Andrews ... communication takes a significant step forward with the authors, ... gestural communication of non-humans, applied here to a group ...
Cached Biology News:Father involvement in pregnancy could reduce infant mortality 2Free Webinar to Focus on Commercializing University Technology 2Free Webinar to Focus on Commercializing University Technology 3Signal like you mean it 2
...
...
... System is an imaging based plate ... and high throughput screening which can ... The Hamamatsu light sources and cameras ... decades-long experience in photon detection technology. ...
... pCITE-2a-c(+) vectors are designed for enhanced translation of ... e.g. rabbit reticulocyte lysate. The maps for pCITE-2b(+) ... the following exceptions: pCITE-2b(+) is a 3793 bp ... I and Xcm I sites. Subtract 7 bp ...
Biology Products: